Kaposi Sarcoma Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Kaposi Sarcoma Market is segmented by Type, Product (Diagnostics, Treatment), and Geography

Market Snapshot

Kaposi Sarcoma Market Overview
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7 %
Kaposi Sarcoma Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The growing prevalence of the Kaposi Sarcoma and the rising number of patients undergoing organ transplantation procedures as patients undergoing organ transplantations are more susceptible for Kaposi sarcoma, are the major factor attributing the growth of the Kaposi sarcoma market.

According to Global Observatory On Donation And Transplantation, 1,39,024 organs were transplanted globally in 2017, where 90,306 (Kidney), 32,348 (Liver), 7,881 (Heart), 6,084 (Lung), 2,243 (Pancreas), 162 (Small Bowel) transplantations took place. Moreover, a promising number of pipeline studies, growing incidence of HIV-associated Kaposi sarcoma is also a major factor driving Kaposi sarcoma market.

However, a shortage in supply of drugs due to a wide demand-supply gap, lack of awareness about this type of cancer, high cost of the treatment, and diagnosis of Kaposi sarcoma will impede the growth of the market studied globally.

Scope of the Report

As per the scope of the report, Kaposi sarcoma (KS) is cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. These patches, or lesions, are usually red or purple. KS is caused by a virus called human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpes virus (KSHV).

By Type
Epidemic (AIDS-associated) Kaposi sarcoma
Classic (Mediterranean) Kaposi sarcoma
Endemic (African) Kaposi sarcoma
Latrogenic (transplant-related) Kaposi sarcoma
By Product
By Diagnostics
Gastrointestinal endoscopy
By Treatment
Highly Active Antiretroviral Therapy (HAART)
Radiation Therapy
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Highly Active Antiretroviral Therapy (HAART) Segment Holds a Significant Market Share

Kaposi sarcoma (KS) is a common cancer associated with the HIV infection and it is considered as an AIDS-defining condition by the US Centers for Disease Control Guidelines. Numerous advancements in the treatment of AIDS-related Kaposi sarcoma have been attained over the last few years, but the introduction of highly active antiretroviral therapy (HAART) has declined the incidences of AIDS-defining illnesses, including KS.

For individuals with Epidemic (AIDS-associated) Kaposi sarcoma, antiretroviral treatment for HIV/AIDS is generally used prior to any other therapies for treating the tumor and to reduce the symptoms. HAART might be given as individual therapy or in the combination with chemotherapy depending on the spread of the disease and the patient’s symptoms. Seldom, HAART might worsen the condition of the Kaposi sarcoma and the pre-existing infections which leads to a condition called immune reconstitution inflammatory syndrome (IRIS).

Kaposi Sarcoma Market Key Trends

North America holds Largest Market Share in Global Kaposi Sarcoma Market

North America region holds a major market share in the Kaposi treatment market globally. Major factors contributing to this position are the increasing number of product approvals, the presence of many numbers of market players in the market, a high number of R&D initiatives undergoing the treatment and the diagnosis of the Kaposi sarcoma. Additionally, the increasing prevalence of Kaposi sarcoma and HIV is also bolstering the market growth in the region. For instance, According to the American Cancer Society's (ACS) publication, about 1 in 200 transplant recipients in the United States develops Kaposi sarcoma.

Kaposi Sarcoma Market Growth Rate

Competitive Landscape

Kaposi Sarcoma market has rapidly progressed over the last few years. Industry observed significant changes in adopting market strategies such as product developments, mergers, and acquisitions in recent years. For instance, in May 2019, The USFDA granted breakthrough therapy designation to Celgene’s pomalidomide (Pomalyst) for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative Kaposi sarcoma.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Incidence of HIV-Associated Kaposi Sarcoma

      2. 4.2.2 Rising Number of Patients Undergoing Organ Transplantation Procedures

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost Of The Treatment And Diagnosis Of Kaposi Sarcoma

      2. 4.3.2 Shortage In Supply Of Drugs Due To Wide Demand-Supply Gap

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type

      1. 5.1.1 Epidemic (AIDS-associated) Kaposi sarcoma

      2. 5.1.2 Classic (Mediterranean) Kaposi sarcoma

      3. 5.1.3 Endemic (African) Kaposi sarcoma

      4. 5.1.4 Latrogenic (transplant-related) Kaposi sarcoma

    2. 5.2 By Product

      1. 5.2.1 By Diagnostics

        1. Biopsy

        2. Bronchoscopy

        3. Gastrointestinal endoscopy

        4. Others

      2. 5.2.2 By Treatment

        1. Highly Active Antiretroviral Therapy (HAART)

        2. Radiation Therapy

        3. Chemotherapy

        4. Immunotherapy

        5. Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Merck & Co., Inc.

      2. 6.1.2 Celgene Corporation

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 Navidea Biopharmaceuticals, Inc.

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 Bristol-Myers Squibb

      7. 6.1.7 Pfizer Inc.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Kaposi Sarcoma Market market is studied from 2018 - 2026.

The Kaposi Sarcoma Market is growing at a CAGR of 7% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Bristol-Myers Squibb, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Pfizer Inc., Navidea Biopharmaceuticals, Inc. are the major companies operating in Kaposi Sarcoma Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!